Zevra Therapeutics Non Currrent Assets Other Over Time
| ZVRA Stock | 9.33 0.17 1.79% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Zevra Therapeutics Performance and Zevra Therapeutics Correlation. Zevra |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. If investors know Zevra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zevra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.13) | Revenue Per Share 0.575 | Quarterly Revenue Growth 0.276 | Return On Assets (0.33) | Return On Equity (1.31) |
The market value of Zevra Therapeutics is measured differently than its book value, which is the value of Zevra that is recorded on the company's balance sheet. Investors also form their own opinion of Zevra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Zevra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zevra Therapeutics' market value can be influenced by many factors that don't directly affect Zevra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zevra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Non Currrent Assets Other Analysis
Compare Zevra Therapeutics and related stocks such as Transcode Therapeutics, Fortress Biotech, and Akebia Ther Non Currrent Assets Other Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RNAZ | (1.0) | (1.0) | (1.0) | (1.0) | (1.0) | (1.0) | (1.0) | (1.0) | (1.0) | (1.0) | 211.4 K | 0.0 | 0.0 | 111.9 K | 71.1 K |
| FBIO | 349 K | 349 K | 349 K | 104 K | 14.7 M | 14.8 M | 16.3 M | 18 M | 16.4 M | 17.7 M | 2.7 M | 3.4 M | 3.7 M | 6.7 M | 7.6 M |
| AKBA | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 305 K | 1.4 M | 1.3 M | 812 K | 21.8 M | 76 M | 38 M | 49.8 M | 5.4 M | 12.4 M | 20.8 M |
| RVPH | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.8 K | 1.6 K | 1.5 K |
| GLUE | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 5.3 M | 278 K | 4.9 M | 3.2 M |
| PMVP | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 221 K | 313 K | 190 K | 243.3 K |
| PHVS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 1.0 | 1.0 | 1.15 | 1.21 |
| TYRA | 125 K | 125 K | 125 K | 125 K | 125 K | 125 K | 125 K | 125 K | 125 K | 125 K | 21 K | 555 K | 4.3 M | 6 M | 6.3 M |
| MOLN | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | (1.9 M) | (1.9 M) | (1.9 M) | (5 M) | (5 M) | (9.7 M) | 1000 | (7.5 M) | 212 K | 222.6 K |
| STOK | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 204 K | 205 K | 205 K | 569 K | 569 K | 654.4 K | 373.5 K |
| ANTX | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 667 K | 1 M | 915.7 K |
| PASG | 34 K | 34 K | 34 K | 34 K | 34 K | 34 K | 34 K | 34 K | 34 K | 11.8 M | 5.2 M | 6.2 M | 4.3 M | 433 K | 411.4 K |
| FDMT | 105 K | 105 K | 105 K | 105 K | 105 K | 105 K | 105 K | 105 K | 429 K | 677 K | 602 K | (58.5 M) | 1.1 M | 684 K | 718.2 K |
| CCCC | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 3.8 M | 4.8 M | 6.2 M | 4.1 M |
| FHTX | 566 K | 566 K | 566 K | 566 K | 566 K | 566 K | 566 K | 566 K | 566 K | 11 K | 842 K | 2.4 M | 8 M | 2.8 M | 2.7 M |
| STTK | 23 K | 23 K | 23 K | 23 K | 23 K | 23 K | 23 K | 23 K | 23 K | 90 K | 349 K | 381 K | 3.1 M | 2.5 M | 2.7 M |
Zevra Therapeutics and related stocks such as Transcode Therapeutics, Fortress Biotech, and Akebia Ther Non Currrent Assets Other description
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.My Equities
My Current Equities and Potential Positions
| Zevra Therapeutics | ZVRA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Florida; U.S.A |
| Exchange | NASDAQ Exchange |
null 9.33
Check out Zevra Therapeutics Performance and Zevra Therapeutics Correlation. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Zevra Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.